Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors - Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies

被引：0

作者：

Tanaka, Yoshiya ^{[1
]}

Takeuchi, Tsutomu

Amano, Koichi ^{[3
]}

Sato, Eri ^{[4
]}

Nawata, Masao ^{[5
]}

Nagasawa, Hayato ^{[6
]}

Hoshi, Daisuke ^{[7
]}

Saito, Kazuyoshi

Fukuyo, Shunsuke

Hanami, Kentaro ^{[5
]}

Kameda, Hideto

Kurasawa, Takahiko ^{[6
]}

Kaneko, Yuko ^{[2
]}

Yamanaka, Hisashi ^{[4
]}

机构：

[1] Univ Occupat & Environm Hlth, Fukuoka, Japan

[2] Keio Univ, Sch Med, Shinjuku Ku, Tokyo, Japan

[3] Saitama Med Univ, Saitama Med Ctr, Saitama, Japan

[4] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo, Japan

[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan

[6] Saitama Med Ctr, Kawagoe, Saitama, Japan

[7] Tokyo Womens Med Univ, Tokyo, Japan

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1239

引用

页码：S484 / S484

页数：1

共 50 条

[41] Cost comparison between two anti-tumor necrosis factor (anti-TNF) therapies in patients with psoriasis using average sales price
Tang, B.
Rahman, M., I
Thompson, H. C.
Hilliard, R.
Naim, A.
Dabbous, O.
VALUE IN HEALTH, 2007, 10 (06) : A468 - A469
[42] Abatacept has beneficial effects in rheumatoid arthritis patients with an inadequate response to anti-TNFα therapy -: Comment
Emery, P
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (06) : 768 - 768
[43] Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in Anti-TNF-Naive rheumatoid arthritis
Fernandez-Nebro, Antonio
Irigoyen, Maria V.
Urena, Inmaculada
Belmonte-Lopez, Maria A.
Coret, Virginia
Jimenez-Nunez, Francisco G.
Diaz-Cordoves, Gisela
Lopez-Lasanta, Maria A.
Ponce, Antonio
Rodriguez-Perez, Manuel
Calero, Enrique
Gonzalez-Santos, Pedro
JOURNAL OF RHEUMATOLOGY, 2007, 34 (12) : 2334 - 2342
[44] Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Finckh, A.
Ciurea, A.
Brulhart, L.
Moller, B.
Walker, U. A.
Courvoisier, D.
Kyburz, D.
Dudler, J.
Gabay, C.
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (02) : 387 - 393
[45] Health Insurance Coverage Limitations of Anti-Integrin Therapy in Ulcerative Colitis and Their Impact on Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Utilization
John, Eric
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S371 - S371
[46] Reactivation of Hepatitis B (HBV) in Patients Treated with Anti-Tumor Necrosis Factor (anti-TNF) Agents
Pauly, Mary Patricia
Tucker, Lue-Yen
Szpakowski, Jean-Luc
Baer, David
Ready, Joanna B.
Hwang, Jessica P.
Lok, Anna S.
HEPATOLOGY, 2014, 60 : 232A - 233A
[47] The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: Results from the arrive trial
Schiff, M.
Pritchard, C.
Teng, J.
Bahrt, K.
Genovese, M.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 89 - 89
[48] Cutaneous manifestations of anti-tumor necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD): A case series
Peer, F. C.
Subramaniam, K.
Pavli, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 108 - 108
[49] Loss of anti-tumour necrosis factor (TNF) drugs into faeces and its impact on anti-TNF serum levels and clinical response in Crohn's disease patients
Chaparro, M.
Guerra, I.
Bujanda, L.
Cabriada, J. L.
Taxonera, C.
Marin-Jimenez, I.
Linares, P. M.
Ramas, M.
Gisbert, J. P.
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S183 - S184
[50] Safety of Rituximab in Patients Failing with an Inadequate Response to One Anti-TNF Agent: Data from a Joint Canadian and Swedish Cohort
Haraoui, B.
Bokarewa, M.
Kallmeyer, I.
Bykerk, V.
JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2572 - 2572

← 1 2 3 4 5 →